Vaxxinity Alzheimer’s treatment shows promising results in early trial

[cafead]

via Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).

article source